Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

van Heek, 1997, In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461, J Pharmacol Exp Ther, 283, 157 van Heek, 2000, Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663, Br J Pharmacol, 129, 1748, 10.1038/sj.bjp.0703235 van Heek, 2001, Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function, Br J Pharmacol, 134, 409, 10.1038/sj.bjp.0704260 Knopp, 2001, Effect of ezetimibe on serum concentrations of lipid-soluble vitamins, Atherosclerosis, 2, 90, 10.1016/S1567-5688(01)80226-9 Zhu, 1999, The effect of gender on the pharmacokinetics of SCH 58235, a cholesterol absorption inhibitor (abstr), S24 Zhu, 2000, Effect of SCH 58235 on the activity of drug metabolizing enzymes in vivo, Clin Pharmacol Ther, 67, 152 Kosoglou, 2001, Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe, Atherosclerosis, 2, 38, 10.1016/S1567-5688(01)80026-X Bauer, 2001, Ezetimibe does not affect the pharmacokinetics or pharmacodynamics of warfarin, Clin Pharmacol Ther, 69, P5 Kosoglou, 2001, Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications, Atherosclerosis, 2, 89 Statkevich, 2001, Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide, Clin Pharmacol Ther, 68, P67 Keung, 2001, Ezetimibe does not affect the pharmacokinetics of oral contraceptives, Clin Pharmacol Ther, 69, P55 Kosoglou, 2001, zetimibe does not alter the pharmacokinetics and pharmacodynamics of digoxin (abstr), 3 Krishna G, Kosoglou T, Ezzet F, Pember L, Statkevich P, Boutros T, Maxwell SE, Basso L, Batra VK. Effect of cimetidine on the pharmacokinetics of ezetimibe (abstr). AAPS Pharmaceutical Science 2001 AAPS Annual Meeting Supplement. 2001;3. Available at: http://www.aapspharmaceutica.com/search/abstract_view.asp?id=304 Dujovne, 2001, Ezetimibe, a selective cholesterol absorption inhibitor, improves plasma lipids in hypercholesterolemic patients, Circulation, 104, 176 Knopp, 2001, Ezetimibe reduces low-density lipoprotein cholesterol, Atherosclerosis, 2, 38, 10.1016/S1567-5688(01)80027-1 Davidson, 2002, Ezetimibe co-administered with simvastatin in 668 patients with primary hypercholesterolemia, J Am Coll Cardiol, 39, 226A, 10.1016/S0735-1097(02)81010-5 Ballantyne, 2002, Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia, J Am Coll Cardiol, 39, 227A, 10.1016/S0735-1097(02)81011-7 1993, Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection evaluation, andtreatment of high blood cholesterol in adults (Adult Treatment Panel II), JAMA, 269, 3015, 10.1001/jama.1993.03500230097036 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 1998, Management of dyslipidemia in adults with diabetes, Diabetes Care, 21, 179, 10.2337/diacare.21.1.179 Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 1994, Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 344, 1383 1999 NHLBI Obesity Education Expert Panel. Treatment guidelines. In: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, MD: National Institutes of Health/National Heart, Lung, and Blood Institute, 1998;98-4083:56–93 Garnett, 1995, Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors, Am J Health-Syst Pharm, 52, 1639, 10.1093/ajhp/52.15.1639 Omar, 2001, Rhabdomyolysis, and HMG-CoA reductase inhibitors, Ann Pharmacother, 35, 1096, 10.1345/aph.10228